FGF23 and X-linked hypophosphatemia: Burosumab, a fully human monoclonal antibody against FGF23, was approved in 2018 for the treatment of XLH in the United States, European Union, and Canada (conditions of approval vary), >3 years after the surveys used in this study were created.